Isabella A. Gashaw - Publications

Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease.

Journal: International journal of molecular sciences

Published: September 05, 2025

Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD.

Journal: European journal of endocrinology

Published: August 01, 2025

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 13, 2025

ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2.

Journal: Investigative ophthalmology & visual science

Published: July 09, 2024

Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test.

Journal: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

Published: March 19, 2024

Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men.

Journal: British journal of clinical pharmacology

Published: November 29, 2023

Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: August 09, 2023

Variability of transient elastography-based spleen stiffness performed at 100 Hz.

Journal: European radiology experimental

Published: July 11, 2023

Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.

Journal: Drugs in R&D

Published: May 28, 2023

The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial.

Journal: Respiratory research

Published: December 22, 2022

The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis.

Journal: Trials

Published: December 10, 2022

Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.

Journal: European journal of endocrinology

Published: December 05, 2022